药物负荷指数(DBI)暴露与结局关联的系统综述
人类研究中,较高DBI与跌倒增加(11/14,71%)、功能较差(31/56,55%)和认知较差(11/20,55%)显著相关;与死亡率、住院时长、衰弱、住院或生活质量降低的关联不一致。动物临床前研究支持较高DBI导致功能和衰弱结局变差。
要点
- 较高DBI与跌倒风险增加、功能和认知结局较差显著相关。
- DBI与死亡率、住院时长、衰弱、住院或生活质量的关联不一致。
- DBI或可用于识别高风险老年人,但研究异质性大无法合并。
核心结论
- 较高DBI可能与跌倒风险增加及功能和认知下降相关。
- 较高DBI与死亡率增加、住院时长、衰弱、住院或生活质量降低的关联不一致。
- 人类观察性功能结局 findings 得到临床前干预研究支持。
- DBI可作为识别高风险老年人的工具。
研究设计与样本
- 纳入报告DBI与临床或处方结局原始数据的研究,对象为任何场景下年龄≥18岁人类或动物。
- 共筛选2382项研究,70项符合纳入标准(65项人类研究、5项动物研究)。
- 使用Joanna Briggs Institute批判性评价工具和SYRCLE偏倚风险工具进行质量评价。
- 因研究人群、场景、研究类型、DBI定义和结局测量异质性显著,采用叙述性综合,结果无法合并。
主要发现
- 人类研究中报告结局包括功能(n=56)、认知(n=20)、跌倒(n=14)、衰弱(n=7)、死亡率(n=9)、生活质量(n=8)、住院(n=7)、住院时长(n=5)、再入院(n=1)、其他临床结局(n=15)和处方结局(n=2)。
- 较高DBI与跌倒增加显著相关(11/14,71%)。
- 较高DBI与功能较差显著相关(31/56,55%)。
- 较高DBI与认知较差显著相关(11/20,55%)。
- 动物研究中报告结局包括功能(n=18)、衰弱(n=2)和死亡率(n=1);临床前研究中较高DBI导致功能和衰弱变差。
关键数值与推荐
- 较高DBI与跌倒增加显著相关(11/14,71%)。
- 较高DBI与功能较差显著相关(31/56,55%)。
- 较高DBI与认知较差显著相关(11/20,55%)。
临床怎么用
- 在老年医学实践中,可考虑使用DBI评估患者抗胆碱能和镇静药物总暴露。
- DBI较高可能提示跌倒、功能和认知下降风险增加,可作为识别高风险老年人的工具。
局限性
- 研究人群、场景、研究类型、DBI定义和结局测量异质性显著,结果无法合并。
- 采用叙述性综合,未进行定量合并。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Drug Burden Index (DBI) measures an individual's total exposure to anticholinergic and sedative medications. This systematic review aimed to investigate the association of the DBI with clinical and prescribing outcomes in observational pharmaco-epidemiological studies, and the effect of DBI exposure on functional outcomes in pre-clinical models. METHODS: A systematic search of nine electronic databases, citation indexes and gray literature was performed (April 1, 2007-December 31, 2022). Studies that reported primary data on the association of the DBI with clinical or prescribing outcomes conducted in any setting in humans aged ≥18 years or animals were included. Quality assessment was performed using the Joanna Briggs Institute critical appraisal tools and the Systematic Review Centre for Laboratory animal Experimentation risk of bias tool. RESULTS: Of 2382 studies screened, 70 met the inclusion criteria (65 in humans, five in animals). In humans, outcomes reported included function (n = 56), cognition (n = 20), falls (n = 14), frailty (n = 7), mortality (n = 9), quality of life (n = 8), hospitalization (n = 7), length of stay (n = 5), readmission (n = 1), other clinical outcomes (n = 15) and prescribing outcomes (n = 2). A higher DBI was significantly associated with increased falls (11/14, 71%), poorer function (31/56, 55%), and cognition (11/20, 55%) related outcomes. Narrative synthesis was used due to significant heterogeneity in the study population, setting, study type, definition of DBI, and outcome measures. Results could not be pooled due to heterogeneity. In animals, outcomes reported included function (n = 18), frailty (n = 2), and mortality (n = 1). In pre-clinical studies, a higher DBI caused poorer function and frailty. CONCLUSIONS: A higher DBI may be associated with an increased risk of falls and decreased function and cognition. Higher DBI was inconsistently associated with increased mortality, length of stay, frailty, hospitalization or reduced quality of life. Human observational findings with respect to functional outcomes are supported by preclinical interventional studies. The DBI may be used as a tool to identify older adults at higher risk of harm.
引用
- Liu BM, Kouladjian O'Donnell L, Redston MR, et al. Association of the Drug Burden Index (DBI) exposure with outcomes: A systematic review. J Am Geriatr Soc. 2023. PMID: 38006299. doi:10.1111/jgs.18691
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。